Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, PR China. * These authors contributed equally to this work.
Guo J, Ma Y, Tang T, Bian Z, Li Q, Tang L, Li Z, Li M, Wang L, Zeng A, Huang S, Guo W. Modulation of immune-responses by DSF/Cu enhances the anti-tumor effects of DTX for metastasis breast cancer. J Cancer 2024; 15(6):1523-1535. doi:10.7150/jca.89120. https://www.jcancer.org/v15p1523.htm
Metastasis has been one of the most important causes of death from breast cancer, and chemotherapy remains the major option for metastatic breast cancer. However, drug resistance and higher toxicity from chemotherapy have been an obstacle for clinical practice, and the combination of chemotherapy with immunotherapy has emerged as a promising treatment strategy. Here, we describe a therapy based on the combination of disulfiram (DSF) and Cu2+ with widely used cytotoxic docetaxel (DTX). DSF/Cu-induced immunogenic cell death promoted the release of type I interferon and human monocyte-induced dendritic cell maturation, which established a foundation for the combination with chemotherapy. Consequently, the combination of DSF/Cu and DTX resulted in significantly more potent anti-tumor effects in 4T1-bearing mice than in single therapy. The present study has shed new light on combining DSF/Cu-induced immune responses with traditional chemotherapeutic agents to achieve greater benefits for patients with metastasis.
Keywords: metastasis breast cancer, immunogenic cell death, disulfiram
Citation styles
APA
Guo, J., Ma, Y., Tang, T., Bian, Z., Li, Q., Tang, L., Li, Z., Li, M., Wang, L., Zeng, A., Huang, S., Guo, W. (2024). Modulation of immune-responses by DSF/Cu enhances the anti-tumor effects of DTX for metastasis breast cancer. Journal of Cancer, 15(6), 1523-1535. https://doi.org/10.7150/jca.89120.
ACS
Guo, J.; Ma, Y.; Tang, T.; Bian, Z.; Li, Q.; Tang, L.; Li, Z.; Li, M.; Wang, L.; Zeng, A.; Huang, S.; Guo, W. Modulation of immune-responses by DSF/Cu enhances the anti-tumor effects of DTX for metastasis breast cancer. J. Cancer 2024, 15 (6), 1523-1535. DOI: 10.7150/jca.89120.
NLM
Guo J, Ma Y, Tang T, Bian Z, Li Q, Tang L, Li Z, Li M, Wang L, Zeng A, Huang S, Guo W. Modulation of immune-responses by DSF/Cu enhances the anti-tumor effects of DTX for metastasis breast cancer. J Cancer 2024; 15(6):1523-1535. doi:10.7150/jca.89120. https://www.jcancer.org/v15p1523.htm
CSE
Guo J, Ma Y, Tang T, Bian Z, Li Q, Tang L, Li Z, Li M, Wang L, Zeng A, Huang S, Guo W. 2024. Modulation of immune-responses by DSF/Cu enhances the anti-tumor effects of DTX for metastasis breast cancer. J Cancer. 15(6):1523-1535.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Global reach, higher impact
